RECURSION PHARMACEUTICALS INC

Company Overview

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company combining high-throughput experimental data with machine learning to accelerate drug discovery and development. Its platform initiatives include Recursion OS 2.0, Virtual Cell expansion and broad uptake of the open-source Boltz-2 model, while internal clinical programs include REC-1245 (RBM39), REC-617 (CDK7 combinations) and REC-102 (ENPP1), and the company also runs multiple partnerships (Sanofi, Roche/Genentech, Bayer, Merck). Recent corporate activity includes the Exscientia acquisition/partial disposal and large patient-dataset purchases (Tempus) to bolster ClinTech capabilities; these moves coincided with 2Q25 revenue of $19.2M (+33% y/y) but materially wider losses and heavy R&D spend, leaving cash of $525.1M at 6/30/25 and a stated need to raise additional capital longer term. Management flags that near-term revenue is volatile and driven by partner milestone timing and clinical catalysts through 2025–2026.

Executive Compensation Practices

Given the heavy R&D spend, negative cash flow and the need for capital, executive pay at a biotech platform company like Recursion is likely skewed toward equity-based compensation (stock options/RSUs) and milestone-linked awards to conserve cash while aligning pay to long-term value creation. Compensation metrics are likely to emphasize clinical and partner milestones, platform adoption (Recursion OS usage, Virtual Cell uptake, milestone receipts from collaborators) and advancement of internal candidates (e.g., Phase 1/2 progress for REC-1245, REC-102). Recent one-time items (Exscientia transaction, Tempus dataset purchases, restructuring/severance) suggest the use of transaction-related bonuses, retention awards and severance protections to manage M&A and integration risk. With an active equity shelf (~$395.9M available) and a stated need for future financing, boards may increasingly use performance-contingent equity grants and longer vesting schedules to retain staff while limiting near-term cash payouts.

Insider Trading Considerations

Insider trading activity at Recursion is likely to cluster around discrete, high-impact events: clinical readouts, partner milestone receipts (which drive lump-sum revenue), M&A milestones and financing announcements; those events create material nonpublic information and typical blackout windows. Expect executives to rely on Rule 10b5-1 plans and pre-announced trading windows to manage tax liquidity from large equity grants (RSU vesting/option exercises), especially given the firm’s equity-heavy pay and recent severance/transaction-related payouts. Watch for insider sales near equity-financing activity (the Citigroup shelf) or after milestone recognition, and for option exercises or sales to cover tax liabilities following large grants; Section 16 reporting and SEC rules will constrain timing, but the presence of MNPI around clinical and partner milestones increases regulatory sensitivity.